Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
342.80
-5.06 (-1.45%)
Aug 6, 2026, 3:27 PM EDT - Market open
Bio-Rad Laboratories Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,589 | 2,583 | 2,567 | 2,671 | 2,802 | 2,923 |
Revenue Growth | 1.37% | 0.65% | -3.92% | -4.67% | -4.12% | 14.81% |
Gross Profit Gross Profit Growth | 1,344 | 1,340 | 1,379 | 1,427 | 1,567 | 1,638 |
Operating Income Operating Income Growth | 53.1 | 47.2 | 269 | 337.8 | 482.6 | 500.34 |
Net Income Net Income Growth | 222.4 | 759.9 | -1,844 | -637.3 | -3,628 | 4,254 |
Earnings Per Share EPS Growth | 8.25 | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 |
EPS Growth | -29.67% | - | - | - | - | 11.35% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Life Science Life Science Growth | 1,010 | 1,021 | 1,028 | 1,178 | 1,347 | 1,401 |
Clinical Diagnostics Clinical Diagnostics Growth | 1,579 | 1,562 | 1,538 | 1,489 | 1,451 | 1,516 |
Other Segments Other Segments Growth | - | - | 0.5 | 3.5 | 4 | 5.8 |
Revenue (Total) Revenue (Total) Growth | 2,589 | 2,583 | 2,567 | 2,671 | 2,802 | 2,923 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,619 | 1,541 | 1,665 | 1,613 | 1,796 | 875.48 |
Total Debt Total Debt Growth | 1,370 | 1,385 | 1,375 | 1,406 | 1,388 | 223.38 |
Net Cash (Debt) Net Cash Growth | 248.1 | 155.9 | 289.8 | 207.2 | 408.12 | 652.1 |
Net Cash Growth | - | -46.20% | 39.87% | -49.23% | -37.41% | -15.42% |
Net Cash Per Share Net Cash Per Share Growth | 9.21 | 5.71 | 10.27 | 7.09 | 13.70 | 21.59 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 492.6 | 532.2 | 455.2 | 374.9 | 194.4 | 669.46 |
Capital Expenditures CapEx Growth | -139.5 | -157.6 | -165.6 | -156.7 | -112.8 | -133.75 |
Free Cash Flow Free Cash Flow Growth | 353.1 | 374.6 | 289.6 | 218.2 | 81.6 | 535.72 |
Free Cash Flow Growth | -4.83% | 29.35% | 32.72% | 167.40% | -84.77% | 12.45% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 51.90% | 51.87% | 53.73% | 53.42% | 55.93% | 56.05% |
Operating Margin | 2.05% | 1.83% | 10.48% | 12.65% | 17.22% | 17.12% |
Pretax Margin | 13.53% | 38.54% | -91.27% | -31.82% | -167.88% | 186.45% |
Profit Margin | 8.59% | 29.42% | -71.86% | -23.86% | -129.45% | 145.57% |
FCF Margin | 13.64% | 14.50% | 11.28% | 8.17% | 2.91% | 18.33% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 41.32 | 10.88 | - | - | - | 5.37 |
Forward PE | 33.11 | 28.94 | 28.85 | 26.51 | 28.66 | 59.87 |
P/FCF Ratio | 26.34 | 21.83 | 31.77 | 42.20 | 152.51 | 42.22 |
PS Ratio | 3.59 | 3.17 | 3.59 | 3.45 | 4.44 | 7.74 |